Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000623 · ClinicalTrials.gov registry record
Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN)
A clinical trial, sponsored by Carelon Research.
- Completed
- Registry status
- 1,000
- Enrollment target
NCT00000623 is a clinical trial that has completed, run by Carelon Research. The registered enrollment target is 1,000 participants.
The verdict
NCT00000623 has completed, sponsored by Carelon Research.
- COMPLETED
- Registry status
- 1,000 participants
- Enrollment target
Study Summary
The purpose of the TCRN is to accelerate research in the management of thalassemia, standardize existing treatments, and evaluate new ones in a network of clinical centers in North America. The emphasis will be on clinical trials that help identify optimal therapy. Therapeutic trials may involve investigational drugs, drugs already approved but not currently used, and drugs currently used.
Interventions
- DRUG Decitabine
- DRUG Deferoxamine
- DRUG Deferiprone
- DRUG Sildenafil
- DRUG Arginine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2000-07 |
| Est. Completion | 2006-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000623
The ClinicalTrials.gov registry entry for NCT00000623 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Carelon Research, which has 50 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Decitabine is the first listed.
NCT00000623 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00000623 about?
NCT00000623 is a clinical study titled "Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN)". The purpose of the TCRN is to accelerate research in the management of thalassemia, standardize existing treatments, and evaluate new ones in a network of clinical centers in North America. The emphasis will be on clinical trials that help identify optimal therapy. Therapeutic trials may involve inv...
What is the current status of trial NCT00000623?
This trial is currently completed. The enrollment target is 1,000 participants. The study started on 2000-07. Estimated completion is 2006-07.
What interventions are being tested in trial NCT00000623?
The interventions under investigation include: Decitabine (DRUG), Deferoxamine (DRUG), Deferiprone (DRUG), Sildenafil (DRUG), Arginine (DRUG).
Who is sponsoring clinical trial NCT00000623?
This trial is sponsored by Carelon Research, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.